Trial reportCirculation2003
Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease.
Trial report in Circulation, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 280 citations in OpenAlex.
- Multimodal ultrasound assessment of myocardial perfusion and contractile function in patients with hypertrophic cardiomyopathy and their first-degree relatives.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers.International journal of molecular sciences · 2024Article
- Comparative analysis of right ventricular strain in Fabry cardiomyopathy and sarcomeric hypertrophic cardiomyopathy.European heart journal. Cardiovascular Imaging · 2023Article
- Cardiac Multimodality Imaging in Hypertrophic Cardiomyopathy: What to Look for and When to Image.Current cardiology reviews · 2023Review
- Article
- Prognostic Value of Left and right ventricular deformation strain analysis on Acute Cellular rejection in Heart Transplant recipients: A 6-year outcome study.The international journal of cardiovascular imaging · 2022Article
- Natural history of hypertrophic cardiomyopathy in cats from rehoming centers: The CatScan II study.Journal of veterinary internal medicine · 2022Article
- Echocardiography in the Diagnosis of Cardiomyopathies: Current Status and Future Directions.Reviews in cardiovascular medicine · 2022Review
- What Aspects of Phenotype Determine Risk for Sudden Cardiac Death in Pediatric Hypertrophic Cardiomyopathy?Journal of cardiovascular development and disease · 2022Review
- Whole-cycle analysis of echocardiographic tissue Doppler velocities as a marker of biological age.Frontiers in cardiovascular medicine · 2022Article
- Preintervention imaging and intraoperative management care of the hypertrophic obstructive cardiomyopathy patient.Asian cardiovascular & thoracic annals · 2022Review
- Echocardiographic tissue imaging evaluation of myocardial characteristics and function in cardiomyopathies.Heart failure reviews · 2021Review
- Point-of-care N-terminal pro B-type natriuretic peptide assay to screen apparently healthy cats for cardiac disease in general practice.Journal of veterinary internal medicine · 2021Article
- Molecular Genetic Basis of Hypertrophic Cardiomyopathy.Circulation research · 2021Article
- Clinical Interpretation and Management of Genetic Variants.JACC. Basic to translational science · 2020Review
- The role of echocardiography for diagnosis and prognostic stratification in hypertrophic cardiomyopathy.Journal of echocardiography · 2020Review
- Article
- Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?The international journal of cardiovascular imaging · 2019Article
- Hypertrophic cardiomyopathy: genetics and clinical perspectives.Cardiovascular diagnosis and therapy · 2019Review
- Multi-modal and multiscale imaging approaches reveal novel cardiovascular pathophysiology inBiology open · 2019Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSystolic (Sa) and diastolic (Ea) myocardial velocities measured by tissue Doppler (TD) imaging (TDI) recently were shown to be decreased in subjects who have mutations causing hypertrophic cardiomyopathy (HCM) but who do not have left ventricular (LV) hypertrophy. By studying these subjects at a later date, we sought to determine whether TDI predicts the subsequent evolution of the HCM phenotype. METHODS AND
resultsSerial 2D and Doppler echocardiography were performed in 12 subjects (age range, 17 to 51 years) with HCM-causing mutations on 2 occasions: before development of hypertrophy and 2 years later. Twelve age- and gender-matched family members without mutations were included as control subjects. In those with mutations, mean septal thickness and LV mass were 1.07+/-0.14 cm and 103.0+/-11 g at baseline, respectively, and increased to 1.30+/-0.36 cm and 193.0+/-78 g at follow-up (P<0.01), with 6 subjects satisfying HCM diagnostic criteria. Sa and Ea velocities in those with mutations were lower compared with control subjects at baseline and follow-up (lateral Sa, 15+/-1.2 versus 8.2+/-2.1 cm/s; lateral Ea, 16.5+/-2.8 versus 8.1+/-2.3 cm/s; P<0.01). At 2 years, left atrial volume and pulmonary venous flow indices of LV filling pressures increased, whereas TD early and late diastolic velocities decreased (all P<0.05) in those with the mutations. Control subjects had no significant interval changes of the above parameters.
conclusionsSubsequent development of HCM in subjects with initially reduced TD velocities establishes TDI as a reliable method for early identification of HCM mutation carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.